UNSPSC 51382503: Tribenoside

This classification denotes a non-steroidal anti-inflammatory agent with the molecular formula C29H34O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Z7N0Y673NU, chemically known as glucofuranoside, ethyl-3,5,6-tri-o-benzyl-, d- but generally known as tribenoside, which bears US NIH Compound Identifier 25145. European Medicines Agency schedules Tribenoside in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11260MIG.

UNSPSC 51382503 Tribenoside (Commodity) appears in state and local procurement records with minimal recent activity directly aligned to this specific pharmaceutical ingredient. The three most recent opportunities tagged under or near this code—a Seminole County naloxone and drug deactivation systems purchase, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescriptions, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products—reflect broader pharmaceutical procurement activity rather than tribenoside-specific sourcing. Tribenoside itself is a veinotonic compound with limited commercial use in the United States, and state and local procurement records show no recent standalone bids or contract awards explicitly naming tribenoside as the deliverable. The issuing bodies represent a mix of county health departments (Seminole County, Florida), state health agencies (Texas HHS Commission), and cooperative purchasing consortia spanning multiple states (MMCAP, which serves Minnesota, Oregon, and other participants), but none of these opportunities target tribenoside directly.

Geographic activity appears concentrated in Texas, Florida, and the MMCAP member states (primarily Minnesota and Oregon), but this reflects general pharmaceutical procurement rather than demand for tribenoside. The Seminole County IFB (IFB60459723LAS, due July 26, 2023) sought naloxone and drug deactivation systems with quarterly deliveries; the Texas HHS RFI (HHS0017013, posted April 3, 2026) explored direct-to-manufacturer prescription programs without naming specific ingredients; and MMCAP's RFP (S1070000015802, due March 26, 2026) solicited generic pharmaceuticals and OTC products through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), with awards effective July 1, 2026. The absence of tribenoside-specific solicitations suggests limited state and local demand for this commodity, and vendors pursuing this code should assess whether their product aligns with general pharmaceutical or specialty veinotonic markets served through cooperative purchasing frameworks rather than standalone government procurement.